Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Connect Biopharma Holdings Limited - Ordinary Shares (NQ:CNTB)

0.9942 -0.1058 (-9.62%)
Delayed Quote Updated: 12:45 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Connect Biopharma Holdings Limited - Ordinary Shares

< Previous 1 2 3 4 5 6 Next >
Top movers analysis one hour before the close of the markets on 2026-09-30: top gainers and losers in today's session. ↗
Via Chartmill
Discover the most active stocks in Wednesday's session. ↗
Via Chartmill
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
Which stocks are gapping on Wednesday? ↗
Via Chartmill
Wednesday's pre-market session: top gainers and losers ↗
Via Chartmill
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
Keep an eye on the top gainers and losers in Tuesday's session. ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
What's going on in today's pre-market session ↗
Via Chartmill
These stocks are moving in today's after hours session ↗
Via Chartmill
News headline image
Connect Biopharma Touts Rademikibart’s Edge as SEABREEZE Data Looms in 2026 ↗
Connect Biopharma (NASDAQ:CNTB) Chief Executive Officer Barry Quart said the company’s rademikibart program continues to show a differentiated clinical and mechanistic profile as the company awaits... 
Via MarketBeat
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Which stocks have an unusual volume on Friday? ↗
Which stocks have an unusual volume on Friday? 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Which stocks are moving before the opening bell on Wednesday? ↗
Wondering what's happening in Wednesday's pre-market session? Find an overview in this article. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Connect Biopharma Posts Q2 Revenue Drop ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Tuesday's after hours session: top gainers and losers ↗
Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Week In Review: EpimAb Sells T-Cell Engager In $635 Million Deal ↗
EpimAb Biotherapeutics sold global rights for a clinical-stage asset to Vignette Bio, a San Francisco startup, in a $635 million deal. Meanwhile, Shenzhen TargetRx raised $20 million by selling China... 
Via Talk Markets
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Week in Review: SystImmune Out-Licenses Global Rights for ADC to BMS in $8.4 Billion Deal ↗
SystImmune, the Seattle arm of Chengdu’s Biokin Pharma, out-licensed global rights (ex-China) for a bispecific ADC to Bristol Myers Squibb in a $8.4 billion agreement. 
Via Talk Markets
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.